Drugmaker seeks approval for China's first biosimilar Ozempic

A drugmaker in China has developed a biosimilar version of Novo Nordisk's (NOVOb.CO), opens new tab popular diabetes drug Ozempic and applied for approval to sell it there, in a potential challenge to Novo's expansion plans in the country.